Charles “Chuck” Allerson is Senior Vice President of Chemistry at DTx Pharma, which was recently acquired by Novartis. Dr. Allerson has spent his career building nucleic acid chemical tools and applying them to the development of viable RNA-based therapeutics. He got his start in RNA therapeutics as a chemist within the Medicinal Chemistry team at Isis (now Ionis) Pharmaceuticals. From there he moved on to lead early-stage and development stage chemistry at Regulus Therapeutics, taking on the role of Director and Head of Chemistry. He subsequently joined Stoke Therapeutics as Vice President of Chemistry, where he helped prepare the TANGO platform for deployment in the clinic, before ultimately ending up at DTx Pharma. DTx is developing the FALCON platform for fatty-acid-mediated delivery of RNA therapeutics to extrahepatic tissues. Dr. Allerson received his Ph.D. in Chemistry from Harvard University and his B.S. degree from Lafayette College.